Fulfilling the Worldwide Promise of Stem Cells
AmStem is a new biotechnology company based in Northern California. It has many unique advantages over other stem cell companies; representing a groundbreaking investment opportunity:
- AmStem controls the largest, fully accredited Cord Blood Bank in the world (more than twice as large as its nearest competitor). Umbilical cord blood is a very popular source of stem cells for research and treatment.
- AmStem is the exclusive distributor of a proven Stem Cell Facial Cream that is fully developed, attractively packaged, and ready for the $21 Billion world market.
- AmStem oversees some of the most advanced Clinical Trials in the world that are using stem cells derived from cord blood to treat many incurable diseases.
- AmStem controls the Patents for the methods used to create the above lines of business, and has many other patents pending.
AmStem Developmental Plans
In September 2009, Stem Cell Therapy International Inc. (OTC: AMST) executed a Reorganization and Stock Purchase Agreement with Histostem Co., Ltd. a Korean company, which will result in one of the first fully merged Pacific Rim stem cell companies and cord blood repositories with a U.S. entity. Following the execution of the Agreement, AmStem – a wholly-owned subsidiary of AMST – will be managing the U.S. operations of Histostem.
AmStem will develop a three-pronged, international strategic platform by using the expertise of its Management Team to improve upon the successes of Histostem:
Join the “Cosmeceuticals” Boom
- AmStem is making connections to partner with a major cosmetic distributor or department store brand, to enter the booming “cosmeceutical” market with the newest, most exciting, and most scientifically valid stem cell beauty product.
- The development of other products by Histostem’s accomplished team of scientists, and/or acquisition of similar, supporting lines of products from other companies is a major objective.
High-Tech Cord Blood Banking
- AmStem will make inroads to link up Histostem’s vast repository of genetically desirable Cord Blood Units (CBUs) with other international networks that provide HLA-typed cord blood samples directly to physicians for the off-label treatment of their patients. A new European Patent was recently awarded to support this.
- These high-quality CBUs, monitored and quality-controlled by a state-of-the-art cryopreservation system, will also be made available to researchers at major hospitals and universities around the world. Two recent hospitals have recently opened the gateway to the vast Chinese medical market by awarding a contract to Histostem.
- Histostem was recently granted a new US Patent for their proprietary method on deriving the maximum number of viable stem cells from a frozen cord blood specimen. This gives AmStem a strategic advantage in controlling one of the most efficient and non-controversial supply chain, storage, and delivery systems for stem cells in the world.
Exciting New Treatments
- AmStem will be generating and monitoring new, improved Clinical Trials to validate and build upon the early successes of Histostem, which has an established pipeline of promising treatments that have already been tested on real patients, including many that are patented in Korea.
- AmStem will focus on developing a novel Hair Restoration clinical trial, using a method that has already been applied for, and is imminently pending a major U.S. Patent.
- Histostem is the only company in the world to have full KFDA approval to use its cord blood derived stem cells directly for the treatment of disease. Clinical trials have been in progress for over 2 years to treat intractable conditions such as Buerger’s Disease, Alzheimer’s and Liver Cirrhosis, as well as Diabetes Mellitus, Hair Restoration and ALS.
|
